Form 4: CG Oncology Executive Acquires 100,000 Stock Options
SEC Form 4 Filing
Joshua F. Patterson, General Counsel and Chief Compliance Officer of CG Oncology, Inc., acquired 100,000 stock options on May 15, 2024.
Summary
- On May 15, 2024, Joshua F. Patterson, General Counsel and Chief Compliance Officer of CG Oncology, Inc., acquired 100,000 stock options.
- The exercise price of these options is $28.01.
- The options vest as to 25% of the underlying shares on June 1, 2025, and the remaining shares vest in 36 substantially similar monthly installments thereafter.
- The expiration date for these options is May 14, 2034.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing, so the sentiment is neutral.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership of securities by a company insider. Such filings are common and provide transparency into the trading activities of company executives.
Stakeholder Impact
- The acquisition of stock options by a company executive can be viewed positively by shareholders as it aligns the executive's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 05/15/2024 | Date of transaction: Joshua F. Patterson acquired 100,000 stock options. |
| 06/01/2025 | Vesting start date: 25% of the stock options begin to vest. |
| 05/14/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.